DV Biomed Past Earnings Performance
Past criteria checks 2/6
DV Biomed has been growing earnings at an average annual rate of 8.1%, while the Biotechs industry saw earnings growing at 17.8% annually. Revenues have been declining at an average rate of 2.1% per year. DV Biomed's return on equity is 14.6%, and it has net margins of 9.9%.
Key information
8.1%
Earnings growth rate
8.7%
EPS growth rate
Biotechs Industry Growth | 12.2% |
Revenue growth rate | -2.1% |
Return on equity | 14.6% |
Net Margin | 9.9% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
How Does DV Biomed Co., Ltd. (GTSM:6539) Stand Up To These Simple Dividend Safety Checks?
Mar 22DV Biomed Co., Ltd.'s (GTSM:6539) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Jan 27DV Biomed's (GTSM:6539) Earnings Are Growing But Is There More To The Story?
Jan 07Should DV Biomed (GTSM:6539) Be Disappointed With Their 37% Profit?
Dec 10Are You An Income Investor? Don't Miss Out On DV Biomed Co., Ltd. (GTSM:6539)
Nov 19Revenue & Expenses BreakdownBeta
How DV Biomed makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1,538 | 153 | 578 | 12 |
30 Sep 23 | 1,649 | 207 | 588 | 13 |
30 Jun 23 | 1,765 | 254 | 606 | 14 |
31 Mar 23 | 1,818 | 268 | 627 | 13 |
31 Dec 22 | 1,866 | 289 | 639 | 13 |
30 Sep 22 | 1,863 | 305 | 624 | 13 |
30 Jun 22 | 1,859 | 321 | 609 | 12 |
31 Mar 22 | 1,843 | 313 | 600 | 12 |
31 Dec 21 | 1,827 | 305 | 591 | 12 |
30 Sep 21 | 1,836 | 281 | 601 | 12 |
30 Jun 21 | 1,845 | 257 | 611 | 11 |
31 Mar 21 | 1,828 | 279 | 619 | 21 |
31 Dec 20 | 1,812 | 301 | 626 | 32 |
30 Sep 20 | 1,811 | 251 | 654 | 55 |
30 Jun 20 | 1,765 | 239 | 643 | 79 |
31 Mar 20 | 1,848 | 203 | 676 | 92 |
31 Dec 19 | 1,930 | 166 | 709 | 105 |
30 Sep 19 | 1,949 | 192 | 694 | 108 |
30 Jun 19 | 1,926 | 154 | 724 | 96 |
31 Mar 19 | 1,896 | 149 | 725 | 86 |
31 Dec 18 | 1,866 | 144 | 726 | 75 |
30 Sep 18 | 1,780 | 176 | 671 | 63 |
30 Jun 18 | 1,779 | 233 | 613 | 63 |
31 Mar 18 | 1,594 | 213 | 527 | 57 |
31 Dec 17 | 1,409 | 193 | 441 | 51 |
30 Sep 17 | 1,252 | 167 | 380 | 45 |
30 Jun 17 | 1,094 | 142 | 319 | 38 |
31 Mar 17 | 1,050 | 169 | 265 | 36 |
31 Dec 16 | 1,003 | 194 | 212 | 35 |
30 Sep 16 | 983 | 207 | 198 | 39 |
30 Jun 16 | 964 | 220 | 184 | 43 |
31 Mar 16 | 887 | 213 | 183 | 40 |
31 Dec 15 | 830 | 207 | 169 | 34 |
30 Sep 15 | 751 | 180 | 173 | 28 |
30 Jun 15 | 673 | 152 | 177 | 22 |
31 Mar 15 | 553 | 105 | 153 | 22 |
31 Dec 14 | 417 | 61 | 141 | 22 |
31 Dec 13 | 131 | 15 | 48 | 10 |
Quality Earnings: 6539 has high quality earnings.
Growing Profit Margin: 6539's current net profit margins (9.9%) are lower than last year (15.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6539's earnings have grown by 8.1% per year over the past 5 years.
Accelerating Growth: 6539's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 6539 had negative earnings growth (-47%) over the past year, making it difficult to compare to the Biotechs industry average (-13.8%).
Return on Equity
High ROE: 6539's Return on Equity (14.6%) is considered low.